Reidy-Lagunes, Diane

Publications

Sort by

Co-Author Network

selected publications

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Investigational new drugs. 2019 Academic Article GET IT
Times cited: 16
Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. PloS one. 2019 Academic Article GET IT
Times cited: 10
Giving Voice to Patient Values Throughout Cancer: A Novel Nurse-Led Intervention. Journal of pain and symptom management. 2019 Academic Article GET IT
Times cited: 19
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 290
Biodistribution and radiation dose estimates for ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. European journal of nuclear medicine and molecular imaging. 2018 Academic Article GET IT
Times cited: 35
Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2018 Academic Article GET IT
Times cited: 26
DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression. Journal of vascular and interventional radiology : JVIR. 2018 Academic Article GET IT
Times cited: 7
Corrigendum to "Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review" [YEJSO 44 (6) (June 2018) 744-749]. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018 Academic Article GET IT
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature genetics. 2018 Academic Article GET IT
Times cited: 109
Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 45
Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018 Academic Article GET IT
Times cited: 8
The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges. 2018 GET IT
Times cited: 14
Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report. 2017 GET IT
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 171
MENIN loss as a tissue-specific driver of tumorigenesis. Molecular and cellular endocrinology. 2017 Review GET IT
Times cited: 11
Commentary: Somatostatin analogs-How we choose, and why. Seminars in oncology. 2017 Academic Article GET IT
Times cited: 1
Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 81
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas. 2017 Academic Article GET IT
Times cited: 25
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. The oncologist. 2017 Academic Article GET IT
Times cited: 29
Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. International journal of radiation oncology, biology, physics. 2017 Academic Article GET IT
Times cited: 42
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017 Academic Article GET IT
Times cited: 89
Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. Journal of surgical oncology. 2016 Academic Article GET IT
Times cited: 38
Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. Journal of oncology practice. 2016 Academic Article GET IT
Times cited: 4
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 175
Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 127
Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Hematology/oncology clinics of North America. 2015 Review GET IT
Times cited: 21
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clinical advances in hematology & oncology : H&O. 2015 Academic Article GET IT
Metastatic insulinoma: current molecular and cytotoxic therapeutic approaches for metastatic well-differentiated panNETs. 2015 GET IT
Times cited: 5
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 95
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer chemotherapy and pharmacology. 2014 Review GET IT
Times cited: 14
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas. 2014 Review GET IT
Times cited: 4
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. Clinical colorectal cancer. 2014 Academic Article GET IT
Times cited: 30
False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Academic Article GET IT
Times cited: 70
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Academic Article GET IT
Times cited: 149
Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2014 Academic Article GET IT
Times cited: 58
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 336
Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. Journal of vascular and interventional radiology : JVIR. 2014 Academic Article GET IT
Times cited: 34
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of hepatology. 2013 Academic Article GET IT
Times cited: 75
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. British journal of cancer. 2013 Academic Article GET IT
Times cited: 99
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clinical colorectal cancer. 2013 Academic Article GET IT
Times cited: 24
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 Conference Paper GET IT
Times cited: 428
The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Seminars in oncology. 2013 Review GET IT
Times cited: 28
In reply. The oncologist. 2013 Letter GET IT
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?. Current oncology reports. 2012 Review GET IT
Times cited: 25
Systemic therapy for advanced pancreatic neuroendocrine tumors: an update. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Review GET IT
Times cited: 11
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 2012 Academic Article GET IT
Times cited: 55
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012 Academic Article GET IT
Times cited: 27
Outcomes of patients undergoing percutaneous biliary drainage to reduce bilirubin for administration of chemotherapy. Journal of vascular and interventional radiology : JVIR. 2011 Academic Article GET IT
Times cited: 35
Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecologic oncology. 2011 Review GET IT
Times cited: 211
Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs. 2011 Review GET IT
Times cited: 10
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer metastasis reviews. 2011 Academic Article GET IT
Times cited: 29
Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Letter GET IT
Times cited: 19
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 121
Thymidylate synthase expression in high-grade neuroendocrine and non-small cell lung cancer histotypes--is it ready for primetime?. Journal of surgical oncology. 2010 Editorial Article GET IT
Times cited: 1
Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. 2009 GET IT
Times cited: 11
Adenocarcinoma of unknown primary in a 20-year-old African American male. 2009 GET IT
Times cited: 1
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nature clinical practice. Oncology. 2009 Review GET IT
Times cited: 27

more ...

less ...

Background

education and training

M.D., State University of New York Health Science Center at Brooklyn 2001
M.S., Tufts University 1996
B.S., Cornell University 1994

Contact

full name

Diane Reidy-Lagunes

VIVO Weill Cornell Medical College

Diane Reidy-Lagunes Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name